Article Information
History
- March 30, 2020.
Article Versions
- Version 1 (March 20, 2020 - 06:18).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Andrea Torneri1,†,
- Pieter Libin2,3,4,†,
- Joris Vanderlocht2,
- Anne-Mieke Vandamme4,5,
- Johan Neyts4 and
- Niel Hens1,2,*
- 1Centre for Health Economic Research and Modelling Infectious Diseases, University of Antwerp, Antwerp, Belgium
- 2Interuniversity Institute of Biostatistics and statistical Bioinformatics, Data Science Institute, Hasselt University, Hasselt, Belgium
- 3Artificial Intelligence lab, Department of computer science, Vrije Universiteit Brussel, Brussels, Belgium
- 4KU Leuven - University of Leuven, Department of Microbiology and Immunology Rega Institute for Medical Research, Clinical and epidemiological virology, Leuven, Belgium
- 5Center for Global Health and Tropical Medicine, Unidade de Microbiologia, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Lisbon, Portugal
- ↵*Materials and Correspondence
Correspondence and material requests should be addressed to Prof. Dr. Niel Hens. Source code of our model and experiments can be found on https://github.com/AndreaTorneri/ViralTransm. email: niel.hens{at}uhasselt.be
Posted March 30, 2020.
A prospect on the use of antiviral drugs to control local outbreaks of COVID-19
